CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease

Delvenne, A; Gobom, J; Schindler, SE; Kate, MT; Reus, LM; Dobricic, V; Tijms, BM; Benzinger, TLS; Cruchaga, C; Teunissen, CE; Ramakers, I; Martinez‐Lage, P; Tainta, M; Vandenberghe, R; Schaeverbeke, J; Engelborghs, S; Roeck, ED; Popp, J; Peyratout, G; Tsolaki, M; Freund‐Levi, Y; Lovestone, S; Streffer, J; Barkhof, F

Neuroscience & Neuroimaging Research Collection

Journal article

CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease

Abstract:: INTRODUCTION: We aimed to unravel the underlying pathophysiology of the neurodegeneration (N) markers neurogranin (Ng), neurofilament light (NfL), and hippocampal volume (HCV), in Alzheimer's disease (AD) using cerebrospinal fluid (CSF) proteomics. METHODS: Individuals without dementia were classified as A+ (CSF amyloid beta [Aβ]42), T+ (CSF phosphorylated tau181), and N+ or N− based on Ng, NfL, or HCV separately. CSF proteomics were generated and compared between groups using analysis of covariance. RESULTS: Only a few individuals were A+T+Ng−. A+T+Ng+ and A+T+NfL+ showed different proteomic profiles compared to A+T+Ng− and A+T+NfL−, respectively. Both Ng+ and NfL+ were associated with neuroplasticity, though in opposite directions. Compared to A+T+HCV−, A+T+HCV+ showed few proteomic changes, associated with oxidative stress. DISCUSSION: Different N markers are associated with distinct neurodegenerative processes and should not be equated. N markers may differentially complement disease staging beyond amyloid and tau. Our findings suggest that Ng may not be an optimal N marker, given its low incongruency with tau pathophysiology. Highlights: In Alzheimer's disease, neurogranin (Ng)+, neurofilament light (NfL)+, and hippocampal volume (HCV)+ showed differential protein expression in cerebrospinal fluid. Ng+ and NfL+ were associated with neuroplasticity, although in opposite directions. HCV+ showed few proteomic changes, related to oxidative stress. Neurodegeneration (N) markers may differentially refine disease staging beyond amyloid and tau. Ng might not be an optimal N marker, as it relates more closely to tau.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Delvenne, A., Gobom, J., Schindler, S. E., Kate, M. T., Reus, L. M., Dobricic, V., Tijms, B. M., Benzinger, T. L. S., Cruchaga, C., Teunissen, C. E., Ramakers, I., Martinez‐Lage, P., Tainta, M., Vandenberghe, R., Schaeverbeke, J., Engelborghs, S., Roeck, E. D., Popp, J., Peyratout, G., … Barkhof, F. (2024). CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

MLA Style

Delvenne, A, et al. “CSF Proteomic Profiles of Neurodegeneration Biomarkers in Alzheimer's Disease.” Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024.

Chicago Style

Delvenne, A, J Gobom, SE Schindler, et al. 2024. “CSF Proteomic Profiles of Neurodegeneration Biomarkers in Alzheimer's Disease.” Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
Print